Top 100 Agencies: Pacific Communications

Share this article:
The website for Allergan's TechAlliance
The website for Allergan's TechAlliance

Pacific Communications' president Ryan Abbate describes 2012 as being a “pretty tumultuous” year. Neverthess, it turned out to be quite a solid one for the Costa Mesa, CA agency, with revenue rising 8% to $56 million.

“It was such an up and down year,” Abbate says. “Budgets were frozen then reinstated. Timelines were truncated. Work started and stopped. There was just a lot of volatility in the business—with virtually all our clients—so managing agency resources was difficult. We shuffled and reshuffled resources to accommodate the varied needs of clients. When all was said it done, we did that effectively and ended up growing the business. In many ways it was our hardest year ever, but it was also our best—revenue hit an all-time high and every metric by which we measure productivity and profitability hit an all-time high.”

There was no shortage of activity on the new business front. That activity included AOR wins for Kimberly-Clark's pain pump I-FLOW and for Allergan Plastic Surgery's suite of breast augmentation and reconstruction products.

The plastic surgery division is one of the few Allergan divisions with which Pacific hadn't previously worked. Existing relationships with Allergan's external disease and dermatology divisions expanded to include global work, and the company also awarded the agency  DTC work on its eyelash enhancer Latisse, based on its performance over the last five years as the brand's professional AOR.

Abbate is pleased that Pacific's integrated business model is working well for many of the agency's clients, even though he recognizes that some of them still feel strongly about parsing out pieces of work.

The changes in Pacific's working relationship with Botox over the past year offer a good example of that tendency. While the agency maintained its professional AOR ­status for the chronic migraine indication of Botox, the digital AOR status for the indication was lost after new management gave the digital business to another agency.

But offering an integrated approach remains central for the agency. “Some clients believe that you have to bifurcate traditional and digital activities, yet we've held the line on integrating them and it's been gratifying to see the result,” he says. “We're doing everything from soup to nuts for many clients, including Latisse and Botox Cosmetic. It makes sense to have all content done with a single agency.”  

Pacific's growth has also extended to its staff. Headcount was up from 208 ending 2011 to 215 last year. It's at about 220 now.

The agency rolled out a new branding campaign last year that highlights its west coast location. Materials challenge existing and prospective employees and clients to “take a left.”

“We're having fun, but it's an important message,” Abbate says of the self-promotion effort. “The idea is to challenge the common wisdom around where the best practices are in healthcare—most people think it's the east coast or Chicago. We can do everything an east coast agency can do.”

The early part of 2013 has been looking a lot like 2012 to Abbate.

“I think we'll be on a roller coaster of sorts that will require really savvy resource management,” he says. “Based on the way this year has started, it's going to a bit of a juggling act. I think that's going to be typical for the future. I expect to end this year at or slightly above last year. When we look at year over year, in the absence of new business we're not seeing increases. If we were to grow 5% in these times I'd be very ­satisfied.”
Share this article:
close

Next Article in Features

Email Newsletters

More in Features

Headliner: Proteus CEO takes an original path

Headliner: Proteus CEO takes an original path

Andrew Thompson, CEO, Proteus Digital Health

Leadership Exchange: How Do We Get Beyond the Pill?

Leadership Exchange: How Do We Get Beyond the ...

As its focus moves from manufacturing to service, pharma needs to partner with healthcare neophytes as well as established players. James Chase asks six experts to assess the risks and ...

FDA and off-label uses: a balancing act

FDA and off-label uses: a balancing act

FDA's current re-examination of its off-label promotion policies in light of the First Amendment is a delicate balancing act between its rock-solid traditional enforcement posture and a diverse new electronic ...